<DOC>
	<DOCNO>NCT01406171</DOCNO>
	<brief_summary>The purpose study determine effect isavuconazole steady state pharmacokinetics midazolam healthy adult subject .</brief_summary>
	<brief_title>Drug Interaction Study Isavuconazole Midazolam</brief_title>
	<detailed_description>Subjects check-in Day -1 remain confined study center completion study procedure Day 14 . Subjects return study center outpatient follow-up visit Day 21 . Blood urine sample take various time study . Subjects receive single dose oral midazolam syrup Day 1 . On Days 3 4 , isavuconazole dose orally three time daily ( TID ) . On Days 5 13 , isavuconazole dose orally daily ( QD ) . A single dose oral midazolam syrup administer Day 12 .</detailed_description>
	<mesh_term>Midazolam</mesh_term>
	<criteria>The subject agree sexual abstinence , surgically sterile , postmenopausal , use medically acceptable method prevent pregnancy study period The subject must weigh least 45 kg body mass index ( BMI ) 1832 kg/m2 The subject 's normal 12lead electrocardiogram ( ECG ) The subject nonsmoker use tobacco nicotine product minimum 6 month The subject 's clinical laboratory test result within normal limit The subject previous history clinically significant gastrointestinal , neurological , renal , hepatic , pulmonary , metabolic , cardiovascular , psychiatric , endocrine , hematological disorder disease , malignancy exclude nonmelanoma skin cancer The subject know suspected hypersensitivity midazolam , isavuconazole , azole class compound The subject history consume 14 unit alcoholic beverage per week , history drug alcohol abuse within past 2 year , positive screen alcohol drug abuse/illegal drug ( Note : one unit = 12 ounce beer , 4 ounce wine 1 ounce spirit ) The subject treatment prescription drug complementary alternative medicine within 14 day prior study drug administration , overthecounter medication within 1 week prior study drug administration , exception acetaminophen 2g/day The subject anticipate inability abstain caffeine alcohol use 48 hour prior clinic admission throughout duration study The subject anticipate inability abstain grapefruit , Seville oranges , star fruit , product contain item 72 hour prior clinic admission throughout duration study The subject has/had symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior clinic admission The subject positive test hepatitis C antibody hepatitis B surface antigen know history human immunodeficiency virus The subject vaccinate within 30 day prior study drug administration The subject receive experimental agent within 30 day five halflives , whichever longer , prior study drug administration The subject significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day , donate plasma within 7 day prior clinic admission The subject condition precludes subject 's participation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Isavuconazole</keyword>
	<keyword>ASP9766</keyword>
	<keyword>BAL8557</keyword>
	<keyword>Midazolam</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>